CTOs on the Move

Legacy Senior Living

www.legacysl.net

 
Since 2002, Legacy Senior Living has specialized in operating Independent Living, Assisted Living & Memory Care facilities throughout the southeast. Founded with a purpose to serve the greatest generation, Legacy take`s the calling seriously, knowing that each resident and family member deserves the highest quality care. Legacy Seeks to serve with honor, respect, faith and integrity through specific programs: Standards of Service, "Going the Extra Mile", and Quality Assurance Programs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.legacysl.net
  • 2235 Candies Lane
    Cleveland, TN USA 37312
  • Phone: 423.478.8071

Executives

Name Title Contact Details

Similar Companies

Cache Valley Specialty Hospital

Cache Valley Specialty Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cache Valley Specialty Hospital is based in Logan, UT. You can find more information on Cache Valley Specialty Hospital at www.cvsh.com

MyHealth Centre

MyHealth Centre is a unique collaborative partnership of medical professionals and health care industry experts established in order to deliver quality and innovation in patient care. MyHealth Centre is a leading manager of independently owned diagnostic imaging facilities in Ontario. We currently manage over 25 Independent Health Facilities (IHFs) with agreements to develop additional IHF licenses.

BROWNING'S PHARMACY

BROWNING'S PHARMACY is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Melbourne, FL. To find more information about BROWNING'S PHARMACY, please visit www.brownings.net

FutureNet Technologies Corporation

FutureNet Technologies Corporation is a Monrovia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.